Tecentriq is a cancer medicine for treating urothelial cancer (a cancer of the bladder and urinary system) and non-small cell lung cancer.
In urothelial cancer that is locally advanced or has spread, Tecentriq is used on its own in patients who have previously been treated with platinum-based cancer medicines or in patients who cannot be treated with cisplatin (a platinum-based medicine) and whose cancer cells (at least 5%) have a protein called PD-L1.
In non-small cell lung cancer that is locally advanced or has spread, Tecentriq is used on its own in patients who have had chemotherapy before. In patients whose cancer has spread and who have not yet had chemotherapy, Tecentriq is used in combination with the cancer medicines bevacizumab, paclitaxel and carboplatin. Patients with non-small cell lung cancer with certain genetic mutations (changes) should have targeted treatments before receiving Tecentriq.
Tecentriq contains the active substance atezolizumab.
Tecentriq : EPAR - Medicine overview (PDF/111.49 KB)
First published: 29/09/2017
Last updated: 17/06/2019
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Roche Registration GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
05/03/2019 Tecentriq - EMEA/H/C/004143 - II/0007/G
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):
- after prior platinum containing chemotherapy, or
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%.
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSLCLC should also have received targeted therapy before receiving Tecentriq.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 201901/02/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 201816/11/2018